JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choe, J.-Y.
Right arrow Articles by Peng, T.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choe, J.-Y.
Right arrow Articles by Peng, T.-C.
Journal of Pharmacology And Experimental Therapeutics, Vol. 189, Issue 3, 593-602, 1974
Copyright © 1974 by American Society for Pharmacology and Experimental Therapeutics


EFFECT OF 5-METHOXYTRYPTAMINE ON SERUM CALCIUM AND PHOSPHATE IN RATS

Jae-Yne Choe 1 and Tai-Chan Peng 1

1 Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina

Injection of 5-methoxytryptamine HCl (5-MT) in a single s.c. dose caused a rapid (within 30 minutes) and prolonged (at least 2-3 hours) hypocalcemia and hyperphosphatemia in rats. The hyperphosphatemic response required at least 5 mg/kg of 5-MT whereas the hypocalcemic response required only 0.2 mg/kg. With pargyline it was possible to dissociate these two responses. Although concurrent administration of pargyline (35 mg/kg i.p.) and 5-MT abolished the hypocalcemia found after 5-MT alone, it strikingly enhanced the 5-MT-induced hyperphosphatemia. Thus the results indicate that production of hyperphosphatemia is not responsible for the fall in serum calcium induced by 5-MT. 5-MT produced hypocalcemia and hyperphosphatemia both in thyroidectomized and parathyroidectomized rats, indicating that these effects were not mediated either by the thyroid or by the parathyroid glands. The effects of 5-MT on serum calcium and phosphate were still evident in acutely nephrectomized rats, indicating that these effects were not mediated by the kidney. Studies using rats labeled with 45Ca showed that 5-MT increased the specific activity of plasma calcium (counts per minute per milligram of calcium) by producing a fall in total calcium but not in 45Ca. The results with 45Ca and the observation that 5-MT counteracted the serum calciumraising effect of parathyroid hormone given to acutely thyroparathyroidectomized rats suggest that 5-MT inhibits calcium mobilization from bone. The hyperphosphatemia must be the result of an action of 5-MT on sites other than bone. Results of structure-activity suggest that the methylation of serotonin at position 5 of the indole nucleus and the presence of a free amino group at position 3 (as represented by 5-MT) are required for the hypocalcemic effect; the amino group may need to be metabolized further since pargyline abolished the hypocalcemic action. The free amino group at position 3 and the concomitant presence of either a hydroxyl or a methoxyl group at position 5 as found in serotonin and 5-MT, respectively, appear to be essential for the production of hyperphosphatemia.

Submitted on August 11, 1973
Accepted on January 24, 1974







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1974 by the American Society for Pharmacology and Experimental Therapeutics.